Testosterone in Women — What It Does, When It Starts Declining, and Why It Has Been Excluded from Women’s Hormonal Care

Women produce testosterone throughout their lives.

In fact, by total volume produced across a lifetime, women produce more testosterone than estrogen.

It has been so thoroughly coded as "the male hormone" — in marketing, in casual conversation, in the architecture of medical research and treatment guidelines — that its gradual decline in women has gone almost entirely unaddressed by medicine, while taking libido, muscle mass, motivation, bone density, and cognitive sharpness with it.

This is the hormone most consistently excluded from the women's hormonal health conversation. And its absence is costing women in ways that are real, measurable, and almost entirely unacknowledged.

What Testosterone Actually Does in the Female Body

Testosterone is an androgen — a steroid hormone class traditionally associated with male physiology but biologically essential in female physiology as well. In women, it is produced by the ovaries (approximately 25%), the adrenal glands (approximately 25%), and through peripheral conversion of precursor hormones, primarily androstenedione and DHEA, in tissues throughout the body (approximately 50%).

Androgen receptors are distributed throughout the female body: in the brain (particularly in regions governing mood, cognition, and motivation), in muscle tissue, in bone, in the cardiovascular system, in the skin, and throughout the genitourinary system including the clitoris and vaginal tissue, where androgen receptor density is comparable to or exceeds that of estrogen receptors in some studies.

This receptor distribution is the physiological basis for testosterone's wide-ranging effects in the female body — and the reason "one-tenth of male levels" is such a misleading framing. Female tissues are calibrated to operate optimally within the female testosterone range. Receptors respond to the female range as normal. Decline below that range produces the same quality of functional consequence that testosterone decline produces in men — it simply does so at a different absolute level.

Libido and Sexual Desire

Testosterone is the primary hormonal driver of sexual desire in women — more directly and consistently than estrogen, which is more associated with vaginal lubrication, tissue health, and the physical comfort of sexual activity than with desire itself.

The clinical significance of this distinction: a woman whose vaginal dryness and discomfort have been addressed with local estrogen may still experience persistently low desire if her testosterone is not addressed — because desire and tissue health are governed by different hormones through different mechanisms. Treating one does not treat the other.

Low testosterone is one of the most common and least treated causes of low libido at midlife — frequently misattributed to relationship dynamics, stress, or aging rather than to its actual hormonal cause.

Muscle Mass and Strength

Testosterone supports skeletal muscle protein synthesis and the maintenance of muscle fiber cross-sectional area. Its decline contributes directly to sarcopenia — age-related loss of muscle mass and strength — through mechanisms independent of and additive to exercise habits and aging alone.

This has a practical consequence that many women describe without connecting it to hormones: the training program that reliably built strength in their 30s produces diminishing returns in their late 40s, despite consistent or even increased effort. The muscle-building hormonal environment has changed. Testosterone decline removes an anabolic signal that was previously supporting training adaptations — and exercise alone cannot fully compensate for the absence of that signal.

Cognitive Drive and Motivation

Testosterone supports dopaminergic reward and motivation circuitry in the prefrontal cortex. Its decline contributes to the flat, unmotivated, low-drive affect that many midlife women experience — the loss of the sense of direction and energy that propelled them through earlier decades — that is frequently diagnosed and treated as depression.

SSRIs address serotonergic and noradrenergic systems. They do not restore androgen-dependent dopaminergic tone. A woman whose flat affect is primarily testosterone-driven may experience limited benefit from antidepressant therapy because the intervention is not addressing the relevant mechanism.

For women with ADHD, this dopaminergic connection adds another layer of hormonal dependency: testosterone's contribution to prefrontal dopamine availability represents an additional hormonal input to a system that is already operating with a narrower margin — meaning testosterone decline may have outsized cognitive and motivational effects in women with ADHD compared to neurotypical women experiencing the same absolute decline.

Bone Density

Testosterone contributes to bone mineral density through two mechanisms: direct androgen receptor-mediated stimulation of osteoblast activity (the bone-building cells), and peripheral aromatization to estradiol in bone tissue — providing a local estrogenic bone protection that is distinct from and additive to systemic estrogen's osteoclast-inhibiting effects.

The loss of testosterone at menopause removes a third protective mechanism from the skeletal system precisely when estrogen and progesterone's protective effects are also being withdrawn — a triple loss that helps explain why post-menopausal bone density decline is as rapid and as significant as it is.

Energy and Vitality

Testosterone supports erythropoiesis (red blood cell production) and has documented effects on mitochondrial biogenesis and function — the cellular machinery responsible for ATP production. Its decline contributes to the generalized fatigue and reduced exercise capacity that many midlife women experience. This fatigue is distinct in character from thyroid-driven or cortisol-driven fatigue and does not fully respond to interventions targeting those systems.

The Decline Timeline That Most Women Do Not Know

Here is what makes testosterone's decline particularly clinically significant: it begins much earlier than estrogen or progesterone decline — and proceeds far more gradually, with less dramatic inflection points.

Testosterone peaks in a woman's mid-20s and then declines steadily from that point. By the time a woman reaches her early 40s, her testosterone may already be approximately 50% of what it was at her peak. This decline occurs quietly, without the visible cycle changes or acute symptoms that signal perimenopausal estrogen and progesterone shifts.

The practical implication: the symptoms of testosterone decline — diminishing libido, reduced muscle responsiveness to training, flattening motivation and drive, subtle energy decline — often begin appearing in a woman's 30s, a full decade or more before she would be considered "perimenopausal" by standard clinical criteria. They are almost never connected to a hormonal cause during this window. They are attributed to busy lifestyles, relationship dynamics, normal aging, or stress.

By menopause, when ovarian androgen production ceases and the adrenal contribution remains as the primary source, the cumulative testosterone deficit is substantial — and its effects on quality of life are often fully expressed before a clinical conversation about it is ever initiated.

Why Testosterone Has Been Left Out of Women's Hormonal Care

The exclusion of testosterone from mainstream women's hormonal healthcare reflects structural, regulatory, and cultural factors that are worth understanding — because they explain why this gap has persisted despite decades of clinical evidence for testosterone's importance in female physiology.

No FDA-approved female product. There is no testosterone product approved by the FDA specifically for use in women in the United States. American practitioners who wish to prescribe testosterone for women must do so off-label, using products formulated and dosed for men (at much lower doses) or compounded preparations. Both carry additional complexity, monitoring requirements, and a prescribing comfort level that not all practitioners have developed.

No standardized female reference ranges. Unlike estrogen and progesterone, for which decades of research have established reasonably characterized hormonal patterns, female testosterone physiology has received comparatively little research investment. The result is a lack of clinical consensus on what constitutes "low" testosterone in women — making practitioners understandably cautious about diagnosing and treating a condition without clear diagnostic criteria.

Cultural coding. The persistent cultural association of testosterone with masculinity has shaped both patient and provider comfort with discussing it in the context of women's health — sometimes producing hesitation to raise the topic even when symptoms are consistent with androgen insufficiency, out of a sense that the conversation is somehow outside the scope of women's hormonal care.

The consequence: millions of women experiencing genuine, biologically explicable symptoms of testosterone insufficiency — low libido, reduced drive, difficulty building muscle, flat motivation, bone density concerns — with limited clinical infrastructure designed to identify, discuss, or address the problem.

How Vita-Fem Restore Addresses Testosterone

Given the diagnostic and regulatory gaps surrounding pharmaceutical testosterone for women, a botanical approach to androgen pathway support offers a meaningfully accessible avenue for addressing testosterone-related symptoms — and for filling a gap that standard menopause care almost universally leaves empty.

Tribulus terrestris: Contains protodioscin and other saponin compounds that have been studied for their potential to support luteinizing hormone (LH) signaling from the pituitary gland. Since LH is the upstream signal that drives ovarian and adrenal androgen production, supporting this signaling pathway represents a physiologically coherent mechanism for supporting the body's own testosterone production rather than introducing exogenous hormone.

Female-specific clinical research on tribulus — including studies conducted specifically in postmenopausal women experiencing sexual dysfunction — has demonstrated improvements in measures of sexual desire, arousal, and satisfaction, distinguishing it from botanicals studied primarily or exclusively in male populations. Its inclusion in Vita-Fem Restore reflects this female-specific evidence base.

Tongkat Ali (Eurycoma longifolia): A Southeast Asian botanical with research supporting its role in testosterone pathway support through complementary mechanisms, including evidence for supporting free testosterone — the biologically active, unbound fraction of circulating testosterone that is available to interact with androgen receptors, as distinct from testosterone bound to SHBG and therefore unavailable for receptor activation.

The free/total testosterone distinction is clinically significant: a woman's total testosterone can appear adequate on a standard panel while her free testosterone — the fraction that actually drives the libido, muscle, motivation, and bone effects — is low, particularly in the context of elevated SHBG. SHBG is itself elevated by estrogen dominance and by the progesterone deficiency that drives it — another connection between the five hormones that standard single-marker testing fails to capture.

Tongkat Ali's documented effects also include improved mood, stress resilience, and cortisol modulation — providing additional support relevant to the cortisol-testosterone interaction described in the cortisol blog post.

Together, tribulus terrestris and Tongkat Ali address the androgen pathway from two complementary mechanistic directions — supporting production through LH signaling and improving availability through free testosterone optimization — in a single formula that makes Vita-Fem Restore one of the very few menopause supplements to address testosterone at all.

Frequently Asked Questions

Do women need testosterone?

Yes. Women produce testosterone throughout their lives and rely on it for libido, muscle mass, bone density, cognitive drive, motivation, and energy. Its gradual decline from the mid-20s onward — and its acceleration at menopause when ovarian production ceases — produces measurable, quality-of-life-altering consequences that are almost entirely absent from the standard clinical conversation about women's hormonal health.

What are the signs of low testosterone in women?

Low libido that is not explained by relationship or psychological factors; reduced motivation and goal-directed drive; difficulty building or maintaining muscle despite consistent exercise; fatigue that feels deeper than ordinary tiredness; a flat, anhedonic quality to daily experience; reduced cognitive sharpness and processing speed. These symptoms often begin in a woman's 30s and intensify through perimenopause and menopause.

Why does testosterone decline in women?

Testosterone peaks in the mid-20s and declines steadily from that point — by approximately 50% by the early 40s — before menopause accelerates the decline further as ovarian androgen production ceases. Chronic cortisol elevation accelerates decline by diverting pregnenolone from androgen synthesis and suppressing the HPG axis that signals sex hormone production.

What is free testosterone and why does it matter more than total testosterone?

Free testosterone is the fraction not bound to sex hormone binding globulin (SHBG) — the protein that carries testosterone in an inactive form. Only free testosterone can bind to androgen receptors and produce biological effects. Total testosterone can appear adequate while free testosterone is low if SHBG is elevated — which is common in estrogen dominance and progesterone deficiency. Tongkat Ali in Vita-Fem Restore supports free testosterone availability by influencing SHBG binding dynamics.

Does tribulus terrestris work for women?

Tribulus terrestris has female-specific clinical research demonstrating improvements in sexual desire, arousal, and satisfaction in women — including postmenopausal women experiencing sexual dysfunction. Its proposed mechanism involves supporting LH signaling from the pituitary to promote ovarian and adrenal androgen production. This female-specific evidence base is why it is included in Vita-Fem Restore rather than being treated as a male-focused fitness ingredient.

Is testosterone addressed in standard menopause HRT?

Not typically. Standard HRT protocols in the United States address estrogen (and often progesterone for uterine protection) but rarely testosterone — in part because there is no FDA-approved female testosterone product. This leaves many women on HRT with improved vasomotor and vaginal symptoms but persistent low libido, reduced motivation, and muscle loss from unaddressed testosterone deficiency. Vita-Fem Restore Menopause Supplement addresses this gap through tribulus terrestris and Tongkat Ali.